Your browser is no longer supported. Please, upgrade your browser.
TransCode Therapeutics, Inc. Common Stock
Index- P/E- EPS (ttm)-1.46 Insider Own35.12% Shs Outstand11.97M Perf Week17.09%
Market Cap38.53M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float2.95M Perf Month27.27%
Income- PEG- EPS next Q- Inst Own- Short Float15.41% Perf Quarter8.78%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.11 Perf Half Y-
Book/sh-1.72 P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range2.35 - 7.00 Perf YTD-39.13%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-54.00% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low37.02% ATR0.32
Employees2 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)55.54 Volatility8.29% 12.89%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.04 Prev Close3.25
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume4.01M Price3.22
Recom- SMA208.80% SMA5010.04% SMA2004.29% Volume177,970 Change-0.92%
Sep-30-21 04:01PM  
Sep-23-21 11:05AM  
Aug-23-21 04:01PM  
Aug-05-21 07:30AM  
Jul-13-21 04:30PM  
Jul-09-21 04:48PM  
Jul-08-21 06:34PM  
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts.